A peptide nanocarrier (MiRGD) successfully delivered an anti-angiogenic gene therapy construct to breast cancer cells, triggering both blood vessel suppression and cancer cell death pathways.
Dual anti-cancer mechanismThe htsFLT01/MiRGD complex simultaneously blocked tumor blood vessel formation (anti-angiogenic) and activated cancer cell death pathways (pro-apoptotic) in breast cancer cells.
What the researchers found
The htsFLT01/MiRGD nanocomplex, delivered at an optimal nitrogen-to-phosphorus (N/P) ratio of 14, successfully transfected MCF7 breast cancer cells and produced dual anti-cancer effects:
1. Anti-angiogenic activity: The htsFLT01 gene encodes sFLT01 protein, which acts as a VEGF decoy receptor to block pathological blood vessel formation that tumors depend on for growth.
2. Pro-apoptotic activity: Expression analysis revealed increased levels of FADD (Fas-Associated Death Domain Protein), CASP8 (Caspase-8), and TP53 (p53) — key genes in the extrinsic apoptotic pathway that triggers programmed cell death.
This dual mechanism suggests a synergistic relationship between blocking tumor blood supply and directly inducing cancer cell death.
Why it matters
Effective cancer gene therapy requires both a therapeutic gene and a safe, efficient delivery system. Peptide-based carriers like MiRGD offer advantages over viral vectors in terms of safety and biocompatibility. The finding that this system activates both anti-angiogenic and apoptotic pathways simultaneously could make it more effective than single-mechanism approaches.
How the study worked
The MiRGD peptide nanocarrier was expressed in E. coli and purified using Ni-NTA affinity chromatography. MCF7 breast cancer cells were transfected with the htsFLT01/MiRGD nanocomplex at an N/P ratio of 14 (previously optimized). Cell lysates were collected and analyzed for expression of apoptosis-related genes (FADD, CASP8, TP53) using gene expression analysis. Statistical analysis was performed using SPSS and REST 2009 software.
What this study cannot tell us
This is an in vitro study using a single breast cancer cell line (MCF7), which may not represent the heterogeneity of breast cancers in patients. No in vivo experiments or animal models were used. The study builds heavily on prior work for construct design and nanocarrier optimization, making it difficult to assess as a standalone study. Specific fold-change values for gene expression increases are not reported in the abstract. No comparison with other delivery systems was included.
How to read the evidence
This is a preliminary in vitro study using a single cancer cell line. While it demonstrates proof-of-concept for the peptide delivery system, it represents very early-stage research with no in vivo validation.
When this study was published
Published in 2025, this is a recent contribution to the rapidly evolving field of peptide-based cancer gene therapy delivery systems.
The bigger picture
Peptide-based nanocarriers are an active area of cancer therapy research, offering the potential for targeted delivery with lower toxicity than viral vectors or synthetic nanoparticles. This study demonstrates that combining anti-angiogenic gene therapy with a tumor-targeting peptide carrier can activate multiple cancer-fighting pathways simultaneously, aligning with the broader trend toward multi-mechanism cancer treatments.
Questions still open
- Does the htsFLT01/MiRGD complex show similar dual-mechanism effects in animal tumor models?
- How does this peptide nanocarrier compare to viral vectors or lipid nanoparticles in terms of delivery efficiency and safety?
- Could this approach be adapted for other cancer types beyond breast cancer?
Common questions
What is a peptide nanocarrier?
How does blocking blood vessel growth fight cancer?
Read the original research
Leveraging the htsFLT01/MiRGD Complex to Enhance Apoptosis and Suppress Angiogenesis in MCF7 Breast Cancer Cells.
Iranian journal of medical sciences, 50(10), 707-712
Citation
Khoshandam, Mohadeseh; Soheili, Zahra-Soheila; Hosseinkhani, Saman; Samiee, Shahram; Latifi-Navid, Hamid; Kalhor, Naser; Soltaninejad, Hossein. (2025). Leveraging the htsFLT01/MiRGD Complex to Enhance Apoptosis and Suppress Angiogenesis in MCF7 Breast Cancer Cells.. Iranian journal of medical sciences, 50(10), 707-712. https://doi.org/10.30476/ijms.2025.105176.3884